Haim_Melman
Deep Breeze– an Israeli company’s innovative medical device could radically change that scenario. Once approved by the US Food and Drug Administration (FDA), the trademarked Breeze@home, will allow COPD and other chronic lung disease patients to stay out of the hospital while receiving continuous remote monitoring by their healthcare provider from home.
“This will not only make life more bearable for them, but will also save the healthcare system a lot of money,” points out the ExScite Dr. Michael Nagler, CEO of Deep Breeze, a medical device company headquartered in Or-Akiva, Israel, with offices in the United States. “We created an immensely simple interface so that the patient can activate transmission by touching just one button,” he explains. “The interface works with voice, text and video so the physician at a remote location can receive measurements and also video conference with the patient to get the full picture.”
In the picture- you can see our own ExScite Haim Melman VP R&D, testing their new monitoring device. To read more click here .
